Cost-effectiveness of left atrial appendage closure with Watchman for non-valvular atrial fibrillation patients in Japan

References

• Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014;11(11):639–654. doi: 10.1038/nrcardio.2014.118.
   PubMed Web of Science ®Google Scholar
• Inoue H, Fujiki A, Origasa H, et al. Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol. 2009;137(2):102–107. doi: 10.1016/j.ijcard.2008.06.029.
   PubMed Web of Science ®Google Scholar
• Fuster V, Rydén LE, Cannom DS, et al. American college of cardiology; American heart association task force on practice guidelines; European society of cardiology committee for practice guidelines; writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation–executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol. 2006;48(4):854–906. doi: 10.1016/j.jacc.2006.07.009.
   PubMed Web of Science ®Google Scholar
• Kamae I, Kitamura A, Sakurai M, et al. Economic burden of atrial fibrillation in Japan. Value Health. 2018;21(Suppl 2):S70. doi: 10.1016/j.jval.2018.07.530.
   Google Scholar
• Yoneda Y, Uehara T, Yamasaki H, et al. Hospital-based study of the care and cost of acute ischemic stroke in Japan. Stroke. 2003;34(3):718–724. doi: 10.1161/01.STR.0000056171.55342.FF.
   PubMed Web of Science ®Google Scholar
• Hattori N, Hirayama T, Katayama Y. Medical care for chronic-phase stroke in Japan. Neurol Med Chir. 2012;52(4):175–180. doi: 10.2176/nmc.52.175.
   PubMed Web of Science ®Google Scholar
• Group JJW. Guidelines for pharmacotherapy of atrial fibrillation (JCS2013). Circ J. 2014;78(8):1997–2021.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200. doi: 10.1093/eurheartj/ehw128.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2019;74(1):104–132. 2019 doi: 10.1016/j.jacc.2019.01.011.
   PubMed Web of Science ®Google Scholar
• Reddy VY, Doshi SK, Kar S, et al. 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70(24):2964–2975. doi: 10.1016/j.jacc.2017.10.021.
   PubMed Web of Science ®Google Scholar
• Reddy VY, Akehurst RL, Armstrong SO, et al. Time to cost-effectiveness following stroke reduction strategies in AF: warfarin versus NOACs versus LAA closure. J Am Coll Cardiol. 2015;66(24):2728–2739. doi: 10.1016/j.jacc.2015.09.084.
   PubMed Web of Science ®Google Scholar
• Reddy VY, Akehurst RL, Armstrong SO, et al. Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. Europace. 2016;18(7):979–986. doi: 10.1093/europace/euv412.
   PubMed Web of Science ®Google Scholar
• Reddy VY, Akehurst RL, Amorosi SL, et al. Cost-effectiveness of left atrial appendage closure with the Watchman device compared with warfarin or non-vitamin K antagonist oral anticoagulants for secondary prevention in nonvalvular atrial fibrillation. Stroke. 2018;49(6):1464–1470. doi: 10.1161/STROKEAHA.117.018825.
   PubMed Web of Science ®Google Scholar
• Freeman JV, Hutton DW, Barnes GD, et al. Cost-effectiveness of percutaneous closure of the left atrial appendage in atrial fibrillation based on results from PROTECT AF versus PREVAIL. Circ Arrhythm Electrophysiol. 2016;9(6):e003407.
   PubMed Web of Science ®Google Scholar
• Reddy VY, Akehurst RL, Gavaghan MB, et al. Cost-effectiveness of left atrial appendage closure for stroke reduction in atrial fibrillation: analysis of pooled, 5-year, long-term data. J Am Heart Assoc. 2019;8(13):e011577.
   PubMed Web of Science ®Google Scholar
• Health Labour Sciences Research Grant (Policy Integrated Science Research Project). “Evaluation Methods for Policy Application of Medical Economic Evaluation and Standardization of Data and Construction of the System” (Research Representative: Takashi Fukuda). The analysis guideline for cost-effectiveness evaluation by the Central Social Insurance Medical Council. 2015. https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku -Iryouka/0000104722.pdf.
   Google Scholar
• Aonuma K, Yamasaki H, Nakamura M, et al. Percutaneous WATCHMAN left atrial appendage closure for japanese patients with nonvalvular atrial fibrillation at increased risk of thromboembolism - first results from the SALUTE trial. Circ J. 2018;82(12):2946–2953. doi: 10.1253/circj.CJ-18-0222.
   PubMed Web of Science ®Google Scholar
• Naganuma M, Shiga T, Sato K, et al. Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: a single-center observational study. Thromb Res. 2012;130(1):21–26. doi: 10.1016/j.thromres.2011.11.005.
   PubMed Web of Science ®Google Scholar
• Core2 Health. Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council. Version 2.0; [cited 2022 May 20]. Available from: https://c2h.niph.go.jp/tools/guideline/guideline_en.pdf.
   Google Scholar
• Boston Scientific. WATCHMAN FLX™ [package insert]; [cited 2021 Sep 2]. Available from:https://www.bostonscientific. com/content/dam/Manuals/us/current-rev-en/50816633-01A_Watchman_IFU_en_s.pdf.
   Google Scholar
• Dennis MS, Burn JP, Sandercock PA, et al. Long-term survival after first-ever stroke: the oxfordshire community stroke project. Stroke. 1993;24(6):796–800. doi: 10.1161/01.str.24.6.796.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867. doi: 10.7326/0003-4819-146-12-200706190-00007.
   PubMed Web of Science ®Google Scholar
• Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154(1):1–11. doi: 10.7326/0003-4819-154-1-201101040-00289.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. doi: 10.1056/NEJMoa0905561.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992. doi: 10.1056/NEJMoa1107039.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. doi: 10.1016/S0140-6736(13)62343-0.
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Bridgers SL, James KE, et al. For the veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327(20):1406–1412. doi: 10.1056/NEJM199211123272002.
   PubMed Web of Science ®Google Scholar
• Singer DE, Hughes RA, Gress DR, et al. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323(22):1505–1511. doi: 10.1056/NEJM199011293232201.
   PubMed Web of Science ®Google Scholar
• Tokano T, Nakazato Y, Kato E, et al. The efficacy and safety of novel anticoagulant “Dabigatran” in patients with atrial fibrillation – three-year experience. Heart. 2015;47:563–569.
   Google Scholar
• Shiga T, Naganuma M, Nagao T, et al. Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: a single-center observational study. J Arrhythm. 2015;31(6):339–344. doi: 10.1016/j.joa.2015.04.004.
   PubMed Web of Science ®Google Scholar
• Stroke prevention in atrial fibrillation investigators. Stroke prevention in atrial fibrillation study: final results. Circulation. 1991;84(2):527–539.
   PubMed Web of Science ®Google Scholar
• Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the copenhagen AFASAK study. Lancet. 1989;1(8631):175–179. doi: 10.1016/s0140-6736(89)91200-2.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18(2):349–355. doi: 10.1016/0735-1097(91)90585-w.
   PubMed Web of Science ®Google Scholar
• MHLW Ministry of Health, Labor and Welfare. Abridged life table 2017; [cited 2019 Jun 17]. Available from:https://www.mhlw.go.jp/toukei/saikin/hw/life/life17/index.html.
   Google Scholar
• Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–1457.
   PubMed Web of Science ®Google Scholar
• Ariesen MJ, Claus SP, Rinkel GJ, et al. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003;34(8):2060–2065. doi: 10.1161/01.STR.0000080678.09344.8D.
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Fukuda T, Ikeda S, et al. Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D. Qual Life Res. 2016;25(3):707–719. doi: 10.1007/s11136-015-1108-2.
   PubMed Web of Science ®Google Scholar
• Noto S, Yanagi H, Tomura S. Measuring utilities for various functional outcomes after stroke. Comparison of rating scale and time trade-off methods. Jpn J Public Health. 2002;49:1205–1216.
   Google Scholar
• Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312(19):1988–1998. doi: 10.1001/jama.2014.15192.
   PubMed Web of Science ®Google Scholar
• Gage BF, Scott JD, Owens DK. Marginal cost-utility of warfarin and aspirin in elderly patients with non-valvular atrial fibrillation. Med Decis Making. 1993;13:386.
   Google Scholar
• O’Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA. 2005;293(6):699–706. doi: 10.1001/jama.293.6.699.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Arant TW, Ellis SL, et al. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics. 2006;24(10):1021–1033. doi: 10.2165/00019053-200624100-00009.
   PubMed Web of Science ®Google Scholar
• The Ministry of Health, Labor and Welfare. April 1, 2020 Notification. Available from: https://www.mhlw.go.jp/content/12400000/000602947.pdf.
   Google Scholar
• Medical Data Vision Co., Ltd.; [cited 2020 Mar 30]. Available from: https://www.mdv.co.jp/mdv_database/english/.
   Google Scholar
• Medical treatment fee point, April 2020. Tokyo: Igakutsushinsya Co. Ltd. 2020.
   Google Scholar
• Kodani E, Atarashi H, Inoue H. J‐RHYTHM registry investigators. Impact of blood pressure control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation: a subanalysis of the J-RHYTHM registry. J Am Heart Assoc. 2016;5:e004075.
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Uozumi R, Hamatani Y, et al. Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients – fushimi AF registry. Circ J. 2017;81(9):1278–1285. doi: 10.1253/circj.CJ-16-1337.
   PubMed Web of Science ®Google Scholar
• The Ministry of Health, Labor and Welfare. Survey of long-term care benefit expenditure, August 2020. https://www.e-stat.go.jp/stat-search/files?page=1&layout=datalist&toukei=00450049&tstat=000001123535&cycle=1&year=20200&month=23070908&tclass1=000001123536&tclass2=000001144553&result_back=1&tclass3val=0.
   Google Scholar
• Hirano T, Kaneko H, Mishina S, et al. Suboptimal anticoagulant management in japanese patients with nonvalvular atrial fibrillation receiving warfarin for stroke prevention. J Stroke Cerebrovasc Dis. 2017;26(10):2102–2110. doi: 10.1016/j.jstrokecerebrovasdis.2017.04.030.
   PubMed Web of Science ®Google Scholar
• Fund. Japan: Demographic Shift Opens Door to Reforms. February International Monetary. 2020; [cited 2020 Feb 29]. Available from: https://www.imf.org/en/News/Articles/2020/02/10/na021020-japan-demographic-shift-opens-door-to-reforms.
   Google Scholar
• Phillips KP, Santoso T, Sanders P, et al. Left atrial appendage closure with WATCHMAN in asian patients: 2 year outcomes from the WASP registry. Int J Cardiol Heart Vasc. 2019;23:100358. doi: 10.1016/j.ijcha.2019.100358.
   PubMed Web of Science ®Google Scholar